Table 3 Descriptive statistics of clinic-pathological factors
Variable | Category | Status | ||||
|---|---|---|---|---|---|---|
Survive | Death | |||||
Count | percent | Count | percent | Total | ||
Pre-existing comorbidity | No | 330 | 83.8% | 23 | 14.6% | 353(63.9%) |
Yes | 64 | 16.2% | 135 | 85.4% | 199(36.1%) | |
Stage of cancer | Stage I | 191 | 48.5% | 61 | 38.6% | 252(45.6%) |
Stage II | 139 | 35.3% | 77 | 48.7% | 216(39.2%) | |
Stage III | 64 | 16.2% | 20 | 12.7% | 84(15.2%) | |
Histologic grade | Grade I | 34 | 8.6% | 24 | 15.2% | 58(10.5%) |
Grade II | 161 | 40.9% | 69 | 43.7% | 230(41.7%) | |
Grade III | 199 | 50.5% | 65 | 41.1% | 264(47.8%) | |
Surgical margin | Free | 255 | 64.7% | 117 | 74.1% | 372(67.4%) |
Involved | 139 | 35.3% | 41 | 25.9% | 180(32.6%) | |
Axillary Node status | Negative | 301 | 76.4% | 117 | 74.1% | 418(75.7%) |
Positive | 93 | 23.6% | 41 | 25.9% | 134(24.3%) | |
BMI at diagnosis | Overweight | 145 | 36.8% | 156 | 98.7% | 301(54.5%) |
Normal | 249 | 63.2% | 2 | 1.3% | 251(45.5%) | |
Number of Positive Lymph nodes involved | <=2 | 93 | 23.6% | 41 | 25.9% | 134(24.3%) |
>=2 | 301 | 76.4% | 117 | 74.1% | 418(75.7%) | |
Tumor size | < 2 cm | 108 | 27.4% | 43 | 27.2% | 151(27.4%) |
2.5-5 cm | 59 | 15.0% | 36 | 22.8% | 95(17.2%) | |
>=5 cm | 227 | 57.6% | 79 | 50.0% | 306(55.4%) | |
Estrogen receptor | Negative | 163 | 41.4% | 83 | 52.5% | 246(44.6%) |
Positive | 161 | 40.9% | 54 | 34.2% | 215(38.9%) | |
Not Determine | 70 | 17.8% | 21 | 13.3% | 91(16.5) | |
Progesterone receptor | Positive | 255 | 64.7% | 68 | 43.0% | 323(58.5%) |
Negative | 139 | 35.3% | 90 | 57.0% | 229(41.5%) | |